Onderstepoort Biological Products (OBP) has launched Respiclos, a combination vaccine designed to address two of the most costly and persistent disease challenges in South African cattle: bovine respiratory disease and clostridial infections.
Unveiled at an industry event on 27 March, the vaccine represents more than a decade of research and development and signals a shift towards integrated, locally relevant animal health solutions.
Simplifying herd health management
Speaking at the launch, OBP CEO Dr Jacob Modumo said the product responds directly to evolving pressures in the livestock sector.
“The livestock industry is facing increasing pressure from biosecurity risks and climate variability. Farmers need solutions that are practical, cost-effective and responsive to these changes.
“Instead of multiple vaccinations, we need combination products that make it easier for farmers to protect their herds effectively,” he said.
Built for local conditions
Unlike imported vaccines, Respiclos has been developed using locally relevant strains, ensuring its suitability for South African production systems.
“This is a product based on South African isolates and disease challenges, not something adapted from another market,” said Boet Weyers, research and development manager for OBP.
The launch also highlighted the importance of the communal farming sector. “A large percentage of cattle in South Africa are in communal systems. These farmers are critical to food security, and our solutions must work for them,” Modumo said.
Prevention over cure
Dr Mgabadeli Ncube, a veterinarian at OBP, emphasised that stress (caused by weaning, transport, environmental changes or handling) is a major trigger for disease outbreaks.
“When animals are stressed, their immunity drops. That’s when pathogens take advantage,” he explained.
By combining multiple antigens into a single vaccine, Respiclos reduces labour, handling stress and overall vaccination costs. It also supports more responsible use of antibiotics.
“We need to discourage the overuse of antibiotics. Vaccination must be the foundation of sustainable livestock production,” said Ayanda Mbotshelwa, CEO of Thalitha Pharma, an industry representative.
Respiclos is expected to form part of a broader pipeline of locally developed vaccines.
“This is just the beginning. We are building solutions that will support farmers in an increasingly challenging production environment,” Modumo said.
How the vaccine works
The vaccine stimulates the immune system to:
- Activate immune responses
- Produce antibodies
- Establish immune memory
- Provide protection under field conditions
The recommended programme includes:
- Initial dose at three to four weeks of age
- Second dose at six to eight weeks
- Booster at four to six months, followed by annual revaccination
Administered as a 2ml subcutaneous injection, the vaccine is designed for practical field use.
